Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07473973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

StatusTerminated
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Trial terminated Sponsor's reason: Following review of the totality of program data, the sponsor decided to discontinue development of INZ701. The decision was not related to safety. Show 4 more changesShow less
    • Final enrollment: 2 participants (planned 12)
    • Primary completion date changed from estimate of Oct 14, 2026 to Aug 31, 2026
    • Eligibility criteria expanded, about 9 words
    • Site details revised at 2 of 8 sites
  3. Primary completion moved earlier from Sep 11, 2028 to Oct 14, 2026
    • Enrollment closed, study ongoing
    • Study completion moved earlier from Nov 7, 2028 to Oct 14, 2026
    • Site details revised at 8 of 8 sites
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.
Trial Details
NCT Number NCT07473973
Lead Sponsor Inozyme Pharma
Collaborators: BioMarin Pharmaceutical
Conditions
(from sponsor)		 Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy 1
Related terms Arterial calcification of infancy, Hypophosphatemic Rickets, Autosomal Recessive, 1
Enrollment 2 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov